https://www.selleckchem.com/pr....oducts/Hesperadin.ht
0-98.1) and 74.4% (64/86; 95% CI 63.9-83.2), respectively. No treatment-emergent resistance was observed, and CD4 counts remained stable. There were no study drug-related serious adverse events. Three participants experienced drug-related treatment-emergent adverse events that led to premature drug discontinuation. There were no clinically relevant changes from baseline to week 96 in fasting lipid parameters, and the median change in body weight at week 96 was 0.0kg (IQR -2.3, 2.. Median self-reported adherence was 100% (IQR 100-10
Like
Comment
Share
